Who are Securpres's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ProAir, Lopressor, Carvedilol CR, Eraldin, Arotinolol Hydrochloride, Comparator: carvedilol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/indenolol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Securpres — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Securpres (INDENOLOL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: indenolol. Area: Cardiovascular.

phase 2 indenolol Beta-1 adrenergic receptor, Beta-2 adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Securpres (INDENOLOL). Securpres works by blocking the beta-1 adrenergic receptor, which reduces the heart's workload and slows heart rate.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Securpres TARGET	INDENOLOL		phase 2	indenolol	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
ProAir	albuterol	Generic (originally Allen & Hanburys/GSK)	marketed	SABA (Short-acting beta-2 agonist)	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Beta-2 adrenergic receptor	1982-05-05
Lopressor	metoprolol	Generic (originally Ciba-Geigy/Novartis)	marketed	Beta-1 selective blocker	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, 5-hydroxytryptamine receptor 1A	1978-08-07
Carvedilol CR	Carvedilol CR	University of Florida	marketed	Non-selective beta-blocker with alpha-1 blocking activity	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Eraldin	PRACTOLOL		marketed	practolol	Beta-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Arotinolol Hydrochloride	Arotinolol Hydrochloride	Sumitomo Pharma (Suzhou) Co., Ltd.	marketed	Alpha-beta blocker	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Comparator: carvedilol	Comparator: carvedilol	Organon and Co	marketed	Beta-blocker with alpha-1 antagonist activity	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (indenolol class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Securpres — Competitive Intelligence Brief. https://druglandscape.com/ci/indenolol. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing